文献速递核素与放射性配体治疗肿瘤 PET/CT神经核医学

神经内分泌肿瘤的肽受体放射性核素治疗综述

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2020-07-03

本文综述肽受体放射性核素治疗(PRRT)在晚期、转移性或不可手术的进展性神经内分泌肿瘤(NEN)中的临床应用。内容涵盖肿瘤生物学与受体特征、分子PET-CT影像(尤其双示踪剂PET)与诊疗一体化、不同治疗性放射性核素的放射化学及剂量学考量,并讨论WHO 2017分类NET G3、新辅助PRRT、化疗联合PRRT等特殊临床场景。

要点

  • PRRT是晚期/转移性/不可手术进展性NEN的重要治疗手段。
  • 双示踪剂PET([68Ga]-DOTA-TATE/NOC与[18F]-FDG)有助个体化治疗决策。
  • 治疗核素涉及177Lu、90Y及225Ac标记的DOTATATE。

核心结论

  • PRRT已成为晚期、转移性或不可手术的进展性神经内分泌肿瘤的重要治疗方式。
  • NEN的成功临床管理需综合疾病过程与可用条件等多因素进行个体化决策。

研究设计与样本

  • 本文为综述,围绕PRRT在NEN中的基础理解与临床应用方面进行论述。

主要发现

  • 综述重点涵盖肿瘤生物学与受体特征、分子PET-CT影像与诊疗一体化、不同治疗性放射性核素的放射化学及剂量学考量。
  • 特别关注WHO 2017分类NET G3(Ki-67>20%但具高分化特征)、新辅助PRRT、化疗联合PRRT、Sandwich Chemo-PRRT、duo-PRRT与tandem PRRT等场景。
  • 讨论了耐药性功能性疾病的临床管理细节及如何在特定临床情境中合理倡导PRRT并实现患者个体化管理。

关键数值与推荐

  • WHO 2017分类NET G3定义为Ki-67>20%但具有高分化特征。
  • 治疗性放射性核素包括β发射体177Lu-DOTATATE与90Y-DOTATATE,以及α发射体225Ac-DOTATATE。

临床怎么用

  • 核医学科主治医师应了解PRRT相关临床管理问题及困难病例场景,以高效运行临床PRRT服务。
  • 可利用双示踪剂PET([68Ga]-DOTA-TATE/NOC与[18F]-FDG)探索肿瘤生物学并个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important modality in the therapeutic armamentarium of advanced, metastatic or inoperable, progressive Neuroendocrine Neoplasms (NENs). This review deliberates on the basic understanding and applied clinical aspects of PRRT in NENs, with special reference to (1) tumor biology and receptor characteristics, (2) molecular PET-CT imaging (in particular the invaluable role of dual-tracer PET with [68Ga]-DOTA-TATE/NOC and [18F]-FDG for exploring tumor biology in continuum and individualizing treatment decision making) and NEN theranostics, (3) relevant radiochemistry of different therapeutic radionuclides (both beta emitting 177Lu-DOTATATE and 90Y-DOTATATE and alpha emitting 225Ac-DOTATATE), and (4) related dosimetric considerations. Successful clinical management of the NENs would require multifactorial considerations, and all the aforementioned points pertaining to the disease process and available logistics are key considerations for state-of-the-art clinical practice and delivering personalized care in this group of patients. Emphasis has been placed on relatively intriguing areas such as (1) NET grade 3 of WHO 2017 classification (ie, Ki-67>20% but well-differentiation features), (2) "Neoadjuvant PRRT," (3) combining chemotherapy and PRRT, (4) 'Sandwich Chemo-PRRT', (5) duo-PRRT and tandem PRRT, (6) resistant functioning disease with nuances in clinical management and how one can advocate PRRT rationally in such clinical settings and individualize the management in a patient specific manner. Relevant clinical management issues related to some difficult case scenarios, which the Nuclear Medicine attending physician should be aware of to run an efficient clinical PRRT services, are described.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Basu S, Parghane RV, Kamaldeep, et al. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Semin Nucl Med. 2020. PMID: 32768008. doi:10.1053/j.semnuclmed.2020.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。